The announcement of a partnership for a Phase II clinical trial typically signals positive development and progress in a company's pipeline, which can lead to increased investor confidence and a rise in stock price. Given that this news directly involves Oragenics and represents a significant step forward in their clinical development, it is likely to have a positive short-term impact on their stock.